ES2052530T3 - Composiciones farmaceuticas liofilizadas de acidos carboxilicos de fenilquinolina. - Google Patents

Composiciones farmaceuticas liofilizadas de acidos carboxilicos de fenilquinolina.

Info

Publication number
ES2052530T3
ES2052530T3 ES87112367T ES87112367T ES2052530T3 ES 2052530 T3 ES2052530 T3 ES 2052530T3 ES 87112367 T ES87112367 T ES 87112367T ES 87112367 T ES87112367 T ES 87112367T ES 2052530 T3 ES2052530 T3 ES 2052530T3
Authority
ES
Spain
Prior art keywords
lyophilized pharmaceutical
pharmaceutical compositions
carboxylic acids
salt
phenylquinoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES87112367T
Other languages
English (en)
Inventor
Chien-Chin Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Application granted granted Critical
Publication of ES2052530T3 publication Critical patent/ES2052530T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Abstract

LA INVENCION PROPORCIONA PREPARACIONES FARMACEUTICAS LIOFILIZADAS DE ACIDOS FENILQUINOLEINCARBOXILICOS ANTITUMORALES, TALES COMO LA SAL SODICA DEL ACIDO 6-FLUOR2-(2''-FLUOR-1''-BIFENIL-4-IL)-3-METIL-4- QUINOLEINCARBOXILICO, RECONSTITUIBLE PARA DAR FORMULACIONES ACUOSAS INYECTABLES ESTABLES. ESTAS PREPARACIONES CONTIENEN UN ESTABILIZANTE QUE CONSTA ESENCIALMENTE DE UNA SAL BILIAR, TAL COMO EL COLATO O DESOXICOLATO SODICO Y UNA BASE O UN AMORTIGUADOR QUE PORPORCIONARA UN PH COMPRENDIDO ENTRE 8,5 Y 11 CUANDO SE RECONSTITUYE CON AGUA. EL AMORTIGUADOR PREFERIDO ES GLICINA.
ES87112367T 1986-08-28 1987-08-26 Composiciones farmaceuticas liofilizadas de acidos carboxilicos de fenilquinolina. Expired - Lifetime ES2052530T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90125486A 1986-08-28 1986-08-28
US07/060,203 US4889862A (en) 1986-08-28 1987-06-10 Freeze-dried pharmaceutical compositions of phenylquinoline carboxylic acids

Publications (1)

Publication Number Publication Date
ES2052530T3 true ES2052530T3 (es) 1994-07-16

Family

ID=26739681

Family Applications (1)

Application Number Title Priority Date Filing Date
ES87112367T Expired - Lifetime ES2052530T3 (es) 1986-08-28 1987-08-26 Composiciones farmaceuticas liofilizadas de acidos carboxilicos de fenilquinolina.

Country Status (17)

Country Link
US (1) US4889862A (es)
EP (1) EP0261426B1 (es)
JP (1) JP2629005B2 (es)
KR (1) KR950006218B1 (es)
AU (1) AU602715B2 (es)
CA (1) CA1312824C (es)
DE (1) DE3782480T2 (es)
DK (1) DK168655B1 (es)
ES (1) ES2052530T3 (es)
FI (1) FI90824C (es)
GR (1) GR3006608T3 (es)
HU (1) HU199289B (es)
IE (1) IE60490B1 (es)
IL (1) IL83662A (es)
NO (1) NO873626L (es)
NZ (1) NZ221574A (es)
PT (1) PT85612B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861783A (en) * 1988-04-26 1989-08-29 E. I. Du Pont De Nemours And Company 4-quinoline carboxylic acid derivatives useful for treating skin and muco-epithelial diseases
HU206975B (en) * 1991-03-14 1993-03-01 Reanal Finomvegyszergyar Process for producing granulation and veterinary composition comprising water-soluble flumequine complex
AU739673B2 (en) * 1997-02-05 2001-10-18 Kirin Pharma Kabushiki Kaisha Lyophilized compositions containing sphingoglycolipid and process for preparing them
US6417167B1 (en) 1997-02-05 2002-07-09 Kirin Beer Kabushiki Kaisha Lyophilized compositions containing shingoglycolipid and process for preparing them
TWI232102B (en) * 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection
US20060008529A1 (en) * 2004-07-12 2006-01-12 Meyerhoff Mark E Use of additive sites to control nitric oxide release from nitric oxide donors contained within polymers
US20080241208A1 (en) * 2005-06-30 2008-10-02 Charles Shanley Methods, Compositions and Devices For Promoting Anglogenesis
DE602006017886D1 (de) * 2005-12-02 2010-12-09 Michigan Critical Care Consult Polymerzusammensetzungen, überzüge und vorrichtungen und herstellungs- und anwendungsverfahren damit

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US468299A (en) * 1892-02-02 John atkinson
DE433646C (de) * 1923-09-15 1926-09-09 Chem Fab Vorm E Schering Verfahren zur Herstellung in Wasser leicht loeslicher Derivate von Carbonsaeuren derChinolin- und Pyridinreihe
US3681495A (en) * 1969-08-25 1972-08-01 American Home Prod Freeze dried echothiophate iodide compositions
US4036954A (en) * 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
JPS5071816A (es) * 1973-11-02 1975-06-14
AT356278B (de) * 1976-07-12 1980-04-25 Hoffmann La Roche Verfahren zur herstellung von injektions- loesungen
JPS5976017A (ja) * 1983-01-20 1984-04-28 Yamanouchi Pharmaceut Co Ltd 安定なプロスタグランジンｅ類製剤の製法
DE3483704D1 (de) * 1983-07-22 1991-01-17 Du Pont Phenylchinolinsaeure und derivate als antitumormittel.
US4680299A (en) * 1984-04-30 1987-07-14 E.I. Du Pont De Nemours And Company 2-phenyl-4-quinolinecarboxylic acids and pharmaceutical compositions thereof
DE3329952A1 (de) * 1983-08-19 1985-02-28 Behringwerke Ag, 3550 Marburg Verfahren zur verringerung einer truebung in kontrollseren
EP0179583A1 (en) * 1984-10-04 1986-04-30 Merck & Co. Inc. A system for enhancing the water dissolution rate and solubility of poorly soluble drugs

Also Published As

Publication number Publication date
CA1312824C (en) 1993-01-19
PT85612B (pt) 1990-05-31
AU7762287A (en) 1988-03-03
EP0261426A1 (en) 1988-03-30
IL83662A (en) 1991-09-16
FI90824B (fi) 1993-12-31
DE3782480D1 (de) 1992-12-10
FI873701A (fi) 1988-02-29
GR3006608T3 (es) 1993-06-30
DK447887A (da) 1988-02-29
US4889862A (en) 1989-12-26
DE3782480T2 (de) 1993-04-08
IE872290L (en) 1988-02-28
IL83662A0 (en) 1988-01-31
JPS63115816A (ja) 1988-05-20
DK168655B1 (da) 1994-05-16
KR950006218B1 (ko) 1995-06-12
DK447887D0 (da) 1987-08-27
HU199289B (en) 1990-02-28
AU602715B2 (en) 1990-10-25
JP2629005B2 (ja) 1997-07-09
FI90824C (fi) 1994-04-11
HUT45398A (en) 1988-07-28
IE60490B1 (en) 1994-07-27
FI873701A0 (fi) 1987-08-26
NO873626D0 (no) 1987-08-27
KR880002507A (ko) 1988-05-09
EP0261426B1 (en) 1992-11-04
NZ221574A (en) 1989-11-28
NO873626L (no) 1988-02-29
PT85612A (en) 1987-09-01

Similar Documents

Publication Publication Date Title
ES2063146T3 (es) Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico.
ATE244015T1 (de) Formulierungen fuer faktor ix
SE8206697L (sv) Lekemedel med hog loslighet och sett att framstella dessa
AU571225B2 (en) Retro-inverso analogues of the bradykinin potentiating peptide bpp 5a
PL319603A1 (en) Stable aqueous alpha interferon preparations
UY23835A1 (es) Procedimiento para la preparacion de compuesto de acilo
ES2176355T3 (es) Formulaciones de aerosol de peptidos y proteinas.
ES2095566T3 (es) Suspension farmaceutica acuosa para agentes activos farmaceuticos.
MX173433B (es) Composicion acuosa de ibuprofen y procedimiento para su preparacion
ES2123287T3 (es) Derivados 3-benzoil benzofuranicos como antagonistas de la hormona tiroidea.
DE59310197D1 (de) Lagerstabile wässrige pharmazeutische zubereitungen von g-csf
ES2042582T3 (es) Un procedimiento para preparar una composicion de sustancia que tiene una actividad fisiologica y nutricional util.
ES2170822T3 (es) Formulacion liquida de 1,2-bencisotiazolin-3-ona.
ES2052530T3 (es) Composiciones farmaceuticas liofilizadas de acidos carboxilicos de fenilquinolina.
IT1247945B (it) Agente avente attivita' batteriostatica e battericida
IT1187828B (it) Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
PA8451701A1 (es) Formulacion inyectable transparente de compuesto anestesico
ES2093395T3 (es) Esteres de acil carnitinas con alcoholes alifaticos de cadena larga y composiciones farmaceuticas que los contienen con actividad antibacteriana.
ES2134237T3 (es) Composiciones farmaceuticas que contienen acido ursodesoxicolico.
ITRM910430A1 (it) Composizioni farmaceutiche di somatostatina con assorbimento migliorato, loro preparazione e loro impiego
FI943705A (fi) Farmaseuttiset koostumukset
ES2101334T3 (es) Utilizacion terapeutica de la fosforil-l-serina-n-acil-esfingosina.
PE20030092A1 (es) Formulacion de una solucion de inhalacion con una sal de tiotropio
ES2057759T3 (es) Composicion de iontoforesis para aumentar la concentracion de agentes activos en la piel.
DE69105322D1 (de) Iontophoreseverfahren und -zusammensetzung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 261426

Country of ref document: ES